Medpace (NASDAQ:MEDP) Rating Increased to Equal Weight at Barclays

Barclays upgraded shares of Medpace (NASDAQ:MEDP) from an underweight rating to an equal weight rating in a research note issued to investors on Friday morning, MarketBeat.com reports. The brokerage currently has $500.00 price objective on the stock.

A number of other brokerages have also issued reports on MEDP. Leerink Partners lowered their price target on Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 11th. Royal Bank Of Canada started coverage on Medpace in a report on Tuesday. They issued an “outperform” rating and a $522.00 price objective on the stock. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a research note on Friday, February 13th. Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Finally, Robert W. Baird raised shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price target on the stock in a research note on Tuesday, February 10th. Five analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $486.67.

Medpace Price Performance

NASDAQ MEDP traded up $1.21 on Friday, hitting $470.59. The company had a trading volume of 357,081 shares, compared to its average volume of 472,737. The company’s fifty day moving average price is $533.94 and its 200-day moving average price is $538.42. The company has a market capitalization of $13.36 billion, a PE ratio of 30.76, a PEG ratio of 2.25 and a beta of 1.44. Medpace has a 12-month low of $250.05 and a 12-month high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.49. The business had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company’s revenue was up 32.0% compared to the same quarter last year. During the same period last year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts anticipate that Medpace will post 12.29 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of MEDP. Hsbc Holdings PLC purchased a new stake in shares of Medpace in the fourth quarter valued at about $2,164,000. Worthington Financial Partners LLC purchased a new position in Medpace during the fourth quarter worth about $1,082,000. Bayban acquired a new position in Medpace in the 4th quarter valued at about $44,000. Pacer Advisors Inc. grew its stake in shares of Medpace by 38.1% in the 4th quarter. Pacer Advisors Inc. now owns 153,652 shares of the company’s stock valued at $86,299,000 after buying an additional 42,362 shares during the period. Finally, Virtu Financial LLC grew its stake in shares of Medpace by 83.7% in the 4th quarter. Virtu Financial LLC now owns 1,835 shares of the company’s stock valued at $1,031,000 after buying an additional 836 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.